MA33676B1 - Compositions pharmaceutiques comprenant des dérivés de bisphosphonate et du cholécalciférol à dose élevée - Google Patents
Compositions pharmaceutiques comprenant des dérivés de bisphosphonate et du cholécalciférol à dose élevéeInfo
- Publication number
- MA33676B1 MA33676B1 MA34780A MA34780A MA33676B1 MA 33676 B1 MA33676 B1 MA 33676B1 MA 34780 A MA34780 A MA 34780A MA 34780 A MA34780 A MA 34780A MA 33676 B1 MA33676 B1 MA 33676B1
- Authority
- MA
- Morocco
- Prior art keywords
- cholecalciferol
- salts
- acids
- high dose
- diphenylphosphonate
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
La présente invention porte sur des compositions pharmaceutiques pour empêcher ou traiter l'ostéoporose, qui comprennent des composés à base de bisphosphonate tels que les acides risédroniques ou leurs sels, les acides ibandroniques ou leurs sels, ou similaires, et du cholécalciférol à haute dose, et qui doivent être administrés une fois par mois. La présente invention porte également sur des compositions pharmaceutiques pour empêcher ou traiter l'ostéoporose, devant être administrées une fois par mois, comprenant : (a) des granulés contenant du cholécalciférol obtenus par adsorption, sur de la cellulose microcristalline, de la solution obtenue par dissolution, dans l'éthanol ou une solution aqueuse d'éthanol de : (i) 24 000 à 50 000 ui de cholécalciférol ; (ii) un ou plusieurs premiers stabilisants choisis parmi l'acétate de tocophéryle, l'hydroxytoluène butylé et l'hydroxyanisole butylé ; et (iii) un liant ; (b) du mannitol comme second stabilisant ; et (c) des acides risédroniques ou leurs sels ou des acides ibandroniques ou leurs sels.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020090088480A KR101102364B1 (ko) | 2009-09-18 | 2009-09-18 | 비스포스포네이트 유도체 및 고용량의 콜레칼시페롤을 포함하는 약학 조성물 |
PCT/KR2010/003920 WO2011034274A2 (fr) | 2009-09-18 | 2010-06-17 | Compositions pharmaceutiques comprenant des dérivés de bisphosphonate et du cholécalciférol à dose élevée |
Publications (1)
Publication Number | Publication Date |
---|---|
MA33676B1 true MA33676B1 (fr) | 2012-10-01 |
Family
ID=43759131
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA34780A MA33676B1 (fr) | 2009-09-18 | 2012-04-16 | Compositions pharmaceutiques comprenant des dérivés de bisphosphonate et du cholécalciférol à dose élevée |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP2478909B1 (fr) |
KR (1) | KR101102364B1 (fr) |
CN (2) | CN102497867B (fr) |
BR (1) | BR112012003907A2 (fr) |
MA (1) | MA33676B1 (fr) |
MX (1) | MX343184B (fr) |
RU (1) | RU2533230C2 (fr) |
WO (1) | WO2011034274A2 (fr) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101230178B1 (ko) * | 2010-06-10 | 2013-02-06 | 주식회사 네비팜 | 골다공증 예방 또는 치료용 조성물 및 이의 제조방법 |
ITMI20120393A1 (it) * | 2012-03-14 | 2013-09-15 | Tiberio Bruzzese | Formulazioni acquose di bisfosfonati, vitamina d e alcol benzilico adatte all'uso intramuscolare o sottocutaneo |
MX350569B (es) * | 2012-12-03 | 2017-09-11 | Landsteiner Scient S A De C V | Composicion farmaceutica estable para el tratamiento de osteoporosis. |
KR101847947B1 (ko) | 2013-03-15 | 2018-05-28 | 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 | 안정화되고 변형된 비타민 d 방출 제형 |
KR20160144663A (ko) | 2015-06-09 | 2016-12-19 | 최숙 | 제제 및 이의 제조방법 |
IT201600123773A1 (it) * | 2016-12-06 | 2018-06-06 | Abiogen Pharma Spa | Composizione per il trattamento dell’osteoartrosi |
CN108420797B (zh) * | 2018-05-09 | 2022-05-03 | 南京海融制药有限公司 | 维生素d类似物制剂及其制备方法 |
KR102158375B1 (ko) * | 2018-10-25 | 2020-09-21 | 단국대학교 천안캠퍼스 산학협력단 | 비타민 d 에멀젼 및 비스포스포네이트를 포함하는 복합 액상 제형 및 이의 골다공증 예방 또는 치료 용도 |
KR102211287B1 (ko) * | 2018-12-21 | 2021-02-03 | (주)휴온스 | 비타민 d 또는 이의 유도체를 포함하는 안정성이 개선된 액상 제제 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2963718B2 (ja) * | 1990-03-06 | 1999-10-18 | グレラン製薬株式会社 | ビタミンd▲下3▼類含有製剤 |
JP2845342B2 (ja) * | 1990-04-28 | 1999-01-13 | 大正製薬株式会社 | ビタミンd▲下3▼誘導体含有固形製剤組成物 |
KR100317935B1 (ko) | 1999-10-20 | 2001-12-22 | 유승필 | 대사성 골질환 치료용 약제조성물 및 이의 제조방법 |
US20030072802A1 (en) * | 2001-10-11 | 2003-04-17 | R.T. Alamo Ventures, Inc. | Sustained release topiramate |
US20050070504A1 (en) | 2001-12-21 | 2005-03-31 | The Procter & Gamble Co. | Risedronate compositions and their methods of use |
AU2003226148A1 (en) * | 2002-04-05 | 2003-10-27 | Merck & Co., Inc. | Method for inhibiting bone resorption with an alendronate and vitamin d formulation |
GB0330009D0 (en) * | 2003-12-24 | 2004-01-28 | Ferrosan As | Probiotic tablet formulations |
KR20050110814A (ko) | 2004-05-19 | 2005-11-24 | 머크 앤드 캄파니 인코포레이티드 | 골 흡수를 억제하기 위한 조성물 및 방법 |
WO2005117906A1 (fr) | 2004-05-19 | 2005-12-15 | Merck & Co., Inc. | Combinaison pour inhiber la resorption osseuse comprenant un bisphosponate (alendronate) et une vitamine d (cholecalciferol) |
US20050261250A1 (en) | 2004-05-19 | 2005-11-24 | Merck & Co., Inc., | Compositions and methods for inhibiting bone resorption |
WO2008026907A1 (fr) * | 2006-08-29 | 2008-03-06 | Espinosa Abdala Leopoldo De Je | Compositions pharmaceutiques comprenant des bisphosphonates et des vitamines en vue de leur administration hebdomadaire et bimensuelle |
KR100822133B1 (ko) | 2006-11-06 | 2008-04-15 | 한미약품 주식회사 | 비타민 d 또는 이의 유도체의 고체분산체 및비스포스포네이트를 포함하는, 골다공증 예방 또는 치료용복합제제 |
KR100844256B1 (ko) * | 2007-03-23 | 2008-07-07 | 코오롱제약주식회사 | 리세드로네이트와 비타민 d를 포함하는 대사성 골질환치료용 약제조성물 및 이의 제조방법 |
KR101230178B1 (ko) * | 2010-06-10 | 2013-02-06 | 주식회사 네비팜 | 골다공증 예방 또는 치료용 조성물 및 이의 제조방법 |
-
2009
- 2009-09-18 KR KR1020090088480A patent/KR101102364B1/ko active IP Right Grant
-
2010
- 2010-06-17 BR BR112012003907A patent/BR112012003907A2/pt not_active Application Discontinuation
- 2010-06-17 WO PCT/KR2010/003920 patent/WO2011034274A2/fr active Application Filing
- 2010-06-17 EP EP10817343.6A patent/EP2478909B1/fr not_active Not-in-force
- 2010-06-17 MX MX2012002786A patent/MX343184B/es active IP Right Grant
- 2010-06-17 CN CN201080041701.XA patent/CN102497867B/zh not_active Expired - Fee Related
- 2010-06-17 RU RU2012109614/15A patent/RU2533230C2/ru not_active IP Right Cessation
- 2010-06-17 CN CN2013100906878A patent/CN103191138A/zh active Pending
-
2012
- 2012-04-16 MA MA34780A patent/MA33676B1/fr unknown
Also Published As
Publication number | Publication date |
---|---|
KR101102364B1 (ko) | 2012-01-03 |
EP2478909B1 (fr) | 2018-04-25 |
CN102497867B (zh) | 2015-04-29 |
BR112012003907A2 (pt) | 2016-03-22 |
CN103191138A (zh) | 2013-07-10 |
KR20110030852A (ko) | 2011-03-24 |
MX2012002786A (es) | 2012-06-25 |
EP2478909A2 (fr) | 2012-07-25 |
CN102497867A (zh) | 2012-06-13 |
RU2533230C2 (ru) | 2014-11-20 |
RU2012109614A (ru) | 2013-10-27 |
WO2011034274A3 (fr) | 2011-05-19 |
WO2011034274A2 (fr) | 2011-03-24 |
EP2478909A4 (fr) | 2014-02-26 |
MX343184B (es) | 2016-10-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA33676B1 (fr) | Compositions pharmaceutiques comprenant des dérivés de bisphosphonate et du cholécalciférol à dose élevée | |
MA32692B1 (fr) | Procede de liberation d'une composition pharmaceutique a un patient qui en a besoin | |
MA34286B1 (fr) | Compositions pharmaceutiques et procédés pour les fabriquer | |
EP2588116A4 (fr) | Formulations d'une solution intraveineuse de posaconazole stabilisées par une cyclodextrine bêta substituée | |
MA30766B1 (fr) | Formes de dosage pharmaceutiques orales anti-manipulation contenant un analgesique opioide | |
MA34449B1 (fr) | Formulation de poudre seche comprenant un inhibiteur de phosphodiesterase | |
BRPI0514766A (pt) | composições farmacêuticas | |
BR112012018384A2 (pt) | composição farmacêutica sólida com intensificadores e métodos de preparação da mesma. | |
UA96302C2 (en) | Solid dosage form comprising 2-ethoxy-1-{[2'-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl]methyl}-1h-benzimidazole-7-carboxylic acid | |
EA201101672A1 (ru) | Замещенные производные аминомасляной кислоты в качестве ингибиторов неприлизина | |
BRPI0508579A (pt) | composto, composição farmacêutica, e, uso de um composto | |
MA31898B1 (fr) | Compositions pharmaceutiques | |
EA018193B3 (ru) | Соединения и фармацевтические композиции для снижения уровня мочевой кислоты | |
IL179718A0 (en) | Pharmaceutical composition containing irbesartan | |
MA34837B1 (fr) | Composés indoliques ou analogues de ceux-ci utiles dans le traitement de la dégénérescence maculaire liée à l'âge (dmla) | |
MA31780B1 (fr) | Anticorps anti-glypican-3 dont la cinétique dans le plasma est améliorée | |
MA46997B1 (fr) | Préparation de complexes solides de cyclodextrine permettant une administration de substance pharmaceutique active ophtalmique | |
MA31497B1 (fr) | Nouveaux inhibiteurs peptidiques de la replication du virus de l'hepatite c | |
DE602005027727D1 (de) | Zusammensetzungen zur verringerung der toxizität von cisplatin, carboplatin und oxaliplatin | |
MA34296B1 (fr) | Composition retard injectable antipsychotique | |
MA29278B1 (fr) | Composition pharmaceutique comprenant un derive de l'indolylmaleimide | |
MA34313B1 (fr) | Formulation pharmaceutique sous la forme de comprimés bicouches comprenant un inhibiteur de hmg-coa réductase et d'irbésartan | |
MA37317B1 (fr) | Formulation d'anticorps il-17 | |
UA122762C2 (uk) | Пероральна композиція 9-[(2,2-диметилпропіламіно)-метил]-міноцикліну або його солі, тверда пресована дозована форма, композиція для ін'єкцій, застосування та спосіб приготування фармацевтичної композиції | |
FR2984750B1 (fr) | Nouvelles compositions pharmaceutiques comprenant un anticorps liant le recepteur humain de l'hormone anti-mullerienne de type ii |